CPRX Form 144 Filed for 115,000-Share Sale Valued at $2.33M

Rhea-AI Filing Summary

Catalyst Pharmaceuticals (CPRX) Form 144 shows a proposed sale of 115,000 common shares through Fidelity Brokerage Services with an approximate aggregate market value of $2,332,370.02. The filing lists the shares as acquired on 08/26/2025 upon exercise of an option originally granted on 12/19/2018, with the approximate date of sale also listed as 08/26/2025 on the NASDAQ.

The filer certifies no undisclosed material adverse information. No securities were reported sold by the person in the past three months. The notice indicates cash payment for the exercised option and identifies the broker and share count but does not provide the seller's name, percent ownership, or relationship to the issuer.

Positive

• None.

Negative

• Proposed sale of 115,000 common shares with an aggregate market value of $2,332,370.02 could represent insider liquidity.
• Filing does not disclose the seller's name or the seller's ownership percentage, limiting investor context about the significance of the sale.

Insights

Financial Analyst

TL;DR: Proposed sale of 115,000 shares ($2.33M) via exercised option; disclosure is routine and provides liquidity detail without additional financial context.

The Form 144 discloses a planned disposition of 115,000 common shares executed via an option exercise dated 08/26/2025, with proceeds noted as cash and an aggregate market value of $2,332,370.02. This is a standard insider/affiliate disclosure under Rule 144, showing monetization of previously granted equity compensation. The filing omits the filers identity and any ownership percentage, limiting assessment of dilution or signaling. Given the lack of concomitant financial metrics or multiple recent sales, this appears like a routine liquidity event rather than a material corporate development.

Corporate Governance Expert

TL;DR: Form 144 meets Rule 144 reporting requirements for a proposed sale after option exercise but lacks filer identity and ownership context.

The document records the mechanics: option grant date (12/19/2018), acquisition/exercise date (08/26/2025), and intended sale date (08/26/2025) through Fidelity. The signer affirms absence of undisclosed material adverse information and indicates cash payment. For governance review, the absence of the seller's name and relationship to the issuer in the visible content constrains evaluation of potential insider selling motives, compliance with company trading policies, or clustering with other insider transactions. As filed, it documents compliance with Rule 144 notice obligations but leaves contextual governance questions unanswered.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	115000	2332370.02	122391010	08/26/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/26/2025	Option Granted - 12/19/2018	Issuer			115000	08/26/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Catalyst Pharmaceuticals' (CPRX) Form 144 report?

The filing reports a proposed sale of 115,000 common shares through Fidelity with an aggregate market value of $2,332,370.02, approximate sale date 08/26/2025.

How were the shares acquired according to the Form 144?

The shares were acquired by option exercise on 08/26/2025; the option was originally granted on 12/19/2018 and payment was in cash.

Does the filing show recent sales by the same person in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months by the person for whose account the securities are to be sold.

Which broker will handle the proposed sale?

The broker listed is Fidelity Brokerage Services LLC, address shown as 900 Salem Street, Smithfield, RI 02917.

Does the Form 144 include a representation about undisclosed material information?

Yes. The filer represents by signature that they do not know any material adverse information about the issuer that has not been publicly disclosed.